Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Market Closed - Nasdaq Other stock markets 04:00:00 2026-04-10 pm EDT			5-day change	1st Jan Change
7.220 ^USD	-1.50%		+3.14%	-18.14%

Apr. 09	Vanda Asks FDA to Withdraw Proposal Extending Drug Review Timelines	MT
Apr. 08	Vanda Pharmaceuticals Starts Study of Nereus to Address GLP-1 Side Effects	MT

Transcript : Vanda Pharmaceuticals Inc., Q4 2025 Earnings Call, Feb 11, 2026

Published on 02/11/2026 at 07:05 pm EST - Modified on 02/14/2026 at 11:36 am EST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Thank you for standing by. My name is Jordan, and I'll be your conference operator today. At this time, I'd like to welcome Vanda Pharmaceuticals Inc.

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Vanda Pharmaceuticals Inc.

Apr. 09	Vanda Asks FDA to Withdraw Proposal Extending Drug Review Timelines	MT
Apr. 08	Vanda Pharmaceuticals Starts Study of Nereus to Address GLP-1 Side Effects	MT
Apr. 08	Vanda Pharmaceuticals announces initiation of the Thetis study, a clinical trial of Nereus(TM) for the prevention of vomiting induced by GLP-1 receptor agonists	RE
Apr. 08	Vanda Pharmaceuticals Inc. Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS? for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists	CI
Apr. 02	Vanda Pharmaceuticals Inc. Announces Resignation of Timothy Williams as Senior Vice President, General Counsel and Secretary, Effective April 10, 2026	CI
Mar. 30	FDA Issues Final Decision on Vanda Pharmaceuticals? Hearing Request for Tradipitant NDA	CI
Mar. 27	AnaptysBio Board Approves Spin-Off of First Tracks Bio, Repurchase of $100 Million Shares	MT
Mar. 27	EMA's CHMP recommends extension of therapeutic indication for Pfizer's Hympavzi	RE
Mar. 22	Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) added to S&P Biotechnology Select Industry Index	CI
Mar. 05	Truist Initiates Vanda Pharmaceuticals at Buy With $18 Price Target	MT
Mar. 05	Vanda Pharmaceuticals Insider Sold Shares Worth $1,276,971, According to a Recent SEC Filing	MT
Mar. 03	Vanda Pharmaceuticals Inc. Announces FDA Grants Landmark Hearing for HETLIOZin Jet Lag Disorder	CI
Mar. 03	Vanda announces FDA grants landmark hearing for Hetlioz® in jet lag disorder, the first drug approval hearing in over 40 years	RE
Mar. 03	Vanda Pharmaceuticals Wins Rare FDA Hearing on HETLIOZ Application for Jet Lag	MT
Feb. 27	European Medicines Agency Panel Issues Negative Opinion on Vanda's Schizophrenia Treatment	MT